Study: AstraZeneca heart drug more effective than Plavix

05/11/2009 | Reuters

A Phase III trial showed that AstraZeneca's heart drug Brilinta is significantly more effective than blockbuster anti-clotting drug Plavix in reducing risks in patients with acute coronary syndrome. The findings, which will be presented at the European Society of Cardiology's annual meeting in August, could boost Brilinta's chances for approval.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
The Children's Aid Society
New York, NY
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX